SPRAVATO — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson SPRAVATO — Sales to customers (Note 9) increased by 10.5% to $917.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 61.2%, from $569.00M to $917.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand, successful commercial execution, or expanded patient access, while a decrease may signal market saturation, increased competition, or patent expiration.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line to extern...
Peer comparison
Comparable to specific product revenue line items reported by other large-cap pharmaceutical companies, often found in segment disclosures or product-specific revenue tables.
jnj_segment_spravato_sales_to_customers_note_9Historical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $238.00M | $140.00M | $170.00M | $200.00M | $262.00M | $366.00M | $450.00M | $541.00M | $569.00M | $594.00M | $639.00M | $830.00M | $917.00M |
| QoQ Change | — | -41.2% | +21.4% | +17.6% | +31.0% | +39.7% | +23.0% | +20.2% | +5.2% | +4.4% | +7.6% | +29.9% | +10.5% |
| YoY Change | — | — | — | — | +87.1% | +115.3% | — | +106.5% | +55.5% | — | +42.0% | +53.4% | +61.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's spravato — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported spravato — sales to customers (note 9) of $917.00M in Q3 2025.
- How has Johnson & Johnson's spravato — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's spravato — sales to customers (note 9) increased by 61.2% year-over-year, from $569.00M to $917.00M.
- What does spravato — sales to customers (note 9) mean?
- The total revenue earned from selling a specific pharmaceutical product to customers.